Factor IXa inhibitors as novel anticoagulants.

Journal Article (Journal Article;Review)

Currently available anticoagulants are limited by modest therapeutic benefits, narrow clinical applications, increased bleeding risk, and drug-induced thrombophilia. Because factor IX plays a pivotal role in tissue factor (TF)-mediated thrombin generation, it may represent a promising target for drug development. Several methods of attenuating factor IX activity, including monoclonal antibodies, synthetic active site-blocked competitive inhibitors, oral inhibitors, and RNA aptamers, have undergone investigation. This review summarizes present knowledge of factor IX inhibitors with emphasis on biology, pharmacology, preclinical data, and early-phase clinical experience in humans.

Full Text

Duke Authors

Cited Authors

  • Howard, EL; Becker, KCD; Rusconi, CP; Becker, RC

Published Date

  • April 2007

Published In

Volume / Issue

  • 27 / 4

Start / End Page

  • 722 - 727

PubMed ID

  • 17272750

Electronic International Standard Serial Number (EISSN)

  • 1524-4636

Digital Object Identifier (DOI)

  • 10.1161/01.ATV.0000259363.91070.f1


  • eng

Conference Location

  • United States